Investment
Features
FeesSafety
Academy
More
Pluang+

Nearly half of S&P 500 stocks now move opposite the index, signaling unusual market divergence.

Market News
28 Sep 2026
CNBC
View Source
Neutral
Nearly half of S&P 500 stocks now move opposite the index, signaling unusual market divergence.

About 45% of S&P 500 stocks have a negative beta over three months, meaning they move opposite the index. This unusual divergence is driven by heavy concentration in mega-cap tech stocks and sectors like energy, which behave differently from the broader market. Such splits can distort index signals and reflect selective investor focus, especially on AI-related companies. Experts note this pattern echoes past market extremes but caution today's tech firms are more mature, suggesting a different market dynamic.

The story about nearly half the stocks in the S&P 500 moving opposite the market is given context by Pluang's US stock data. Of 150 priced US stocks tradable on Pluang, 35 rose and 115 fell today. META was priced at USD 719.24 with a 1-day change of -4.31%, B was at USD 41.06 with a -4.24% change, and AMD was at USD 604.12 with a -4.20% change, as of Sep 28, 2026 23:13 WIB.

More News

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...

Analyst Insights
Bullish
1 hour ago
Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fi...

Analyst Insights
Bullish
1 hour ago
Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing inter...

Market News
Bullish
2 hours ago
Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...

Analyst Insights
Neutral
2 hours ago
Zcash price drops 9.63% in 24 hours, hitting $1,456 amid $6.5M long liquidations.

Zcash price drops 9.63% in 24 hours, hitting $1,456 amid $6.5M long liquidations.

Zcash (ZEC) experienced a significant price decline of 9.63% over 24 hours, falling from $1,520 to $1,456 within one hour on September 28. This drop was accompanied by $6.5 million in long position liquidations across major exchanges Binance, Bybit, ...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App